LivaNova PLC 10-Q for FY2025 Q3

LivaNova PLC (LIVN)

10-Q 2025-11-05 For: 2025-09-30

Added on April 10, 2026

About this 10-Q

LivaNova PLC filed this 10-Q on November 5, 2025, covering the quarter ended September 30, 2025 (FY2025 Q3).

Headline figures

Quarter ended September 30, 2025, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $357.75M; up 12.5% from $318.12M a year earlier
Net income: $26.78M; down 18.7% from net income of $32.95M a year earlier
Diluted EPS: $0.49; down 18.3% from $0.60 a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →


Large accelerated filer	☑	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐


Class			Outstanding on October 29, 2025
Ordinary Shares - £1.00 par value per share			54,605,527


Item	Description	Page
	Definitions	1
	Intellectual Property, Trademarks, and Trade Names	4
	Cautionary Note About Forward-Looking Statements	5
	PART I. FINANCIAL INFORMATION
1.	Financial Statements (unaudited)	6
2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
3.	Quantitative and Qualitative Disclosures About Market Risk	36
4.	Controls and Procedures	36
	PART II. OTHER INFORMATION
1.	Legal Proceedings	37
1A.	Risk Factors	37
2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
3.	Defaults Upon Senior Securities	37
4.	Mine Safety Disclosures	37
5.	Other Information	37
6.	Exhibits	38
	Signatures	39


Abbreviation						Definition
2015 Plan						LivaNova PLC 2015 Incentive Award Plan
2016 Decision						Decision by the Court of Milan in 2016 to dismiss all legal actions of SNIA and of the Public Administrations and to further require the Public Administrations to pay Sorin €292,000 for legal fees
2021 First Lien Credit Agreement						First Lien Credit Agreement between LivaNova PLC and its wholly-owned subsidiary, LivaNova USA, Inc., and Goldman Sachs Bank USA, as First Lien Administrative Agent and First Lien Collateral Agent, entered into on August 13, 2021
2024 Form 10-K						LivaNova PLC’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 25, 2025
2024 Restructuring Plan						A plan, initiated during the first quarter of 2024, to enhance LivaNova’s focus on its core Cardiopulmonary and Neuromodulation segments
2025 Capped Calls						Privately-negotiated capped call transactions entered into with certain financial institutions
2025 Director Incentive Plan						LivaNova PLC 2025 Director Incentive Plan
2025 Notes						$287.5 million aggregate principal amount 3.00% unsecured cash exchangeable senior notes due December 15, 2025, by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova USA on June 17, 2020
2025 Notes Repurchase Transaction						Repurchase of $230.0 million aggregate principal amount of the 2025 Notes in privately-negotiated transactions from proceeds from the issuance of the 2029 Notes
2029 Capped Calls						Privately-negotiated capped call transactions entered into with certain financial institutions
2029 Notes						$345.0 million aggregate principal amount 2.50% unsecured convertible senior notes due 2029 by private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act, issued by LivaNova PLC on March 8, 2024
A&R 2022 Plan						Amended and Restated LivaNova PLC 2022 Incentive Award Plan

ACS						Advanced Circulatory Support
AHI						Apnea-hypopnea index
ALung						ALung Technologies, Inc.
AOCI						Accumulated other comprehensive income (loss)
ASU						Accounting Standards Update
Barclays						Barclays Bank Ireland PLC
Capped Call Transactions						The 2025 Capped Calls and the 2029 Capped Calls
CEO						Chief Executive Officer
CFO						Chief Financial Officer
CMS						The U.S. Centers for Medicare & Medicaid Services
CODM						Chief Operating Decision Maker

Court of Appeal						Court of Appeal in Milan

Delayed Draw Term Facility						$50.0 million delayed draw term facility under the 2021 First Lien Credit Agreement, resulting from the Incremental Facility Amendment No. 2
DRE						Drug-resistant epilepsy
DTD						Difficult-to-treat depression - The Company’s broader business and strategic communications reference DTD as the preferred disease state when speaking more broadly about depression treatment, as it is a more inclusive and clinically evolving concept that encompasses patients whose depression continues to cause significant burden despite usual treatment efforts. Meanwhile, LivaNova’s RECOVER clinical study defines the patient population using the inclusion criteria for TRD, typically characterized by major depressive disorder that does not adequately respond to at least two different antidepressant treatments given at an appropriate dose and duration. As a result, the Company uses TRD in the context of the RECOVER study to maintain consistency with the study protocol approved by the U.S. Centers for Medicare & Medicaid Services. References to either term in this filing are context-dependent but describe overlapping populations.


Abbreviation						Definition
EBT						LivaNova PLC Employee Benefit Trust
ECJ						European Court of Justice
Embedded Derivatives						The bifurcated embedded derivatives associated with the 2025 Notes and 2029 Notes, collectively


Exchange Act						U.S. Securities Exchange Act of 1934, as amended
FASB						Financial Accounting Standards Board
FX						Foreign currency exchange rate


HLM						Heart-lung machine
ImThera						ImThera Medical, Inc. was a company developing an implantable neurostimulation device system for the treatment of obstructive sleep apnea that LivaNova acquired in 2018
Incremental Facility Amendment No. 2						An incremental facility amendment to the 2021 First Lien Credit Agreement, dated July 6, 2022

Initial Term Facility						$300.0 million term facility under the 2021 First Lien Credit Agreement, resulting from the Incremental Facility Amendment No. 2
ISIN						National Inspectorate for Nuclear Safety and Radiation Protection, a sub-body of the Italian Ministry of Economic Development
LivaNova PLC						A public limited company organized under the laws of England and Wales on February 20, 2015
LivaNova USA						LivaNova USA, Inc.
LSM						LivaNova Site Management S.r.l.
MDL						Federal multi-district litigation in the U.S. District Court for the Middle District of Pennsylvania
MedTech						Medical technology
Ministry						Collectively, the Ministry of Ecological Transition, the Ministry of Economy and Finance, and the Prime Minister’s Office
Nasdaq						Nasdaq Global Select Market

OBBBA						One Big Beautiful Bill Act
ODI						Oxygen desaturation index

Option Counterparties						Certain financial institutions with whom LivaNova USA or LivaNova PLC, as applicable, has entered into the 2025 Capped Calls and 2029 Capped Calls
OSA						Obstructive sleep apnea
OSPREY clinical trial						LivaNova’s clinical trial, “Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation”

Public Administrations						The Italian Ministry of the Environment and other Italian government agencies
R&D						Research and development
Report						This Quarterly Report on Form 10-Q
RSUs						Restricted stock units
SARs						Stock appreciation rights
SEC						U.S. Securities and Exchange Commission
Second A&R 2022 Plan						Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan
Securities Act						U.S. Securities Act of 1933, as amended
SG&A						Selling, general, and administrative expenses

SNIA						SNIA S.p.A.
SNIA Litigation Guarantee						A first demand bank guarantee of €270.0 million in connection with the SNIA environmental litigation
Sorin						Sorin S.p.A.
Term Facilities						The Initial Term Facility, together with the Delayed Draw Term Facility


Abbreviation						Definition
TRD						Treatment-resistant depression - LivaNova’s RECOVER clinical study defines the patient population using the inclusion criteria for TRD, typically characterized by major depressive disorder that does not adequately respond to at least two different antidepressant treatments given at an appropriate dose and duration. As a result, the Company uses TRD in the context of the RECOVER study to maintain consistency with the study protocol approved by the U.S. Centers for Medicare and Medicaid Services. Meanwhile, the Company’s broader business and strategic communications reference DTD as the preferred disease state when speaking more broadly about depression treatment, as it is a more inclusive and clinically evolving concept that encompasses patients whose depression continues to cause significant burden despite usual treatment efforts. References to either term in this filing are context-dependent but describe overlapping populations.
U.S.						United States of America
U.S. GAAP						Generally Accepted Accounting Principles in the U.S.
UK						United Kingdom
USD						U.S. dollar

VNS Therapy						LivaNova Vagus Nerve Stimulation Therapy


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Net revenue	$	357,753	$	318,120	$	1,027,132	$	931,607
Cost of sales	112,898		97,091		327,035		292,492
Gross profit	244,855		221,029		700,097		639,115
Operating expenses:
Selling, general, and administrative	138,522		127,426		405,448		378,238
Research and development	48,577		48,805		133,641		139,206
Other operating expense	3,744		9,180		4,196		29,641
Operating income	54,012		35,618		156,812		92,030
SNIA environmental liability expense	(1,745)		—		(363,815)		—
Interest expense	(10,863)		(15,878)		(38,429)		(47,303)
Loss on debt extinguishment	—		—		(2,651)		(25,482)
Foreign exchange and other income/(expense)	(7,493)		24,701		(332)		12,585
Income (loss) before income tax	33,911		44,441		(248,415)		31,830
Income tax expense	7,114		11,525		24,921		24,469
(Loss) income from equity method investments	(13)		37		(41)		(18)
Net income (loss)	$	26,784	$	32,953	$	(273,377)	$	7,343


Basic income (loss) per share	$	0.49	$	0.61	$	(5.01)	$	0.14
Diluted income (loss) per share	$	0.49	$	0.60	$	(5.01)	$	0.13

Shares used in computing basic income (loss) per share	54,630		54,352		54,529		54,194
Shares used in computing diluted income (loss) per share	55,153		54,585		54,529		54,526


	September 30, 2025		December 31, 2024
ASSETS
Current Assets:
Cash and cash equivalents	$	646,079	$	428,858
Restricted cash	—		294,698
Accounts receivable, net of allowance of $13,313 at September 30, 2025 and $11,275 at December 31, 2024	211,579		193,158
Inventories	167,538		147,566
Prepaid and refundable taxes	27,531		30,544


Prepaid expenses and other current assets	44,422		32,362
Total Current Assets	1,097,149		1,127,186
Property, plant, and equipment, net	218,510		170,260
Goodwill	791,034		750,006
Intangible assets, net	234,530		237,294
Operating lease assets	51,197		46,837
Investments	15,049		25,084
Deferred tax assets	107,305		111,855
Long-term derivative assets	28,011		23,735
Other assets	14,798		14,132
Total Assets	$	2,557,583	$	2,506,389
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Current debt obligations	$	85,440	$	78,004
Accounts payable	88,156		69,726
Accrued liabilities and other	92,229		118,485
SNIA environmental liability	394,587		—
Current contingent consideration	49,041		—
Current litigation provision liability	16,499		12,918
Taxes payable	21,373		32,456
Accrued employee compensation and related benefits	80,263		80,536

Total Current Liabilities	827,588		392,125
Long-term debt obligations	349,031		549,624
Long-term contingent consideration	40,641		84,218

Deferred tax liabilities	10,096		10,915
Long-term operating lease liabilities	43,075		40,105
Long-term employee compensation and related benefits	13,543		12,847
Long-term derivative liabilities	64,515		51,819
Other long-term liabilities	51,864		44,478
Total Liabilities	1,400,353		1,186,131
Commitments and contingencies (Note 5)
Stockholders’ Equity:
Ordinary Shares, £1.00 par value: unlimited shares authorized; 55,503,264 shares issued and 54,605,279 shares outstanding at September 30, 2025; 54,437,670 shares issued and 54,348,542 shares outstanding at December 31, 2024	84,520		83,156
Additional paid-in capital	2,245,024		2,220,658
Accumulated other comprehensive income (loss)	5,508		(80,170)
Accumulated deficit	(1,176,627)		(903,250)
Treasury stock at cost, 897,985 ordinary shares at September 30, 2025; 89,128 ordinary shares at December 31, 2024	(1,195)		(136)
Total Stockholders’ Equity	1,157,230		1,320,258
Total Liabilities and Stockholders’ Equity	$	2,557,583	$	2,506,389


	Balance Sheet Location	September 30, 2025		Fair Value Measurements Using Inputs Considered as:
				Level 1		Level 2		Level 3
Assets:

Derivative assets - capped call derivatives (2025 Notes)	Prepaid expenses and other current assets	$	1,627	$	—	$	—	$	1,627
Derivative assets - capped call derivatives (2029 Notes)	Long-term derivative assets	28,011		—		—		28,011
		$	29,638	$	—	$	—	$	29,638
Liabilities:
Derivative liabilities - freestanding instruments (FX)	Accrued liabilities and other	$	203	$	—	$	203	$	—
Derivative liabilities - embedded derivative (2025 Notes)	Accrued liabilities and other	1,685		—		—		1,685
Derivative liabilities - embedded derivative (2029 Notes)	Long-term derivative liabilities	64,515		—		—		64,515
ImThera contingent consideration arrangement	Current contingent consideration	49,041		—		—		49,041
ImThera contingent consideration arrangement	Long-term contingent consideration	40,641		—		—		40,641
		$	156,085	$	—	$	203	$	155,882


	Capped Call Derivative Assets (2025 Notes)		Capped Call Derivative Assets (2029 Notes)		Embedded Derivative Liability (2025 Notes)		Embedded Derivative Liability (2029 Notes)		ImThera Contingent Consideration Liability
June 30, 2025	$	1,303	$	21,658	$	1,363	$	48,093	$	87,927
Changes in fair value	324		6,353		322		16,422		1,755
September 30, 2025	$	1,627	$	28,011	$	1,685	$	64,515	$	89,682


	Capped Call Derivative Assets (2025 Notes)		Capped Call Derivative Assets (2029 Notes)		Convertible Notes Receivable		Embedded Derivative Liability (2025 Notes)		Embedded Derivative Liability (2029 Notes)		Contingent Consideration Liability
June 30, 2024	$	7,439	$	32,114	$	275	$	10,017	$	95,392	$	81,174
Changes in fair value	(1,668)		(2,517)		(275)		(2,829)		(18,423)		66
September 30, 2024	$	5,771	$	29,597	$	—	$	7,188	$	76,969	$	81,240


Stock Price Volatility (1)	Capped Call Derivative Assets (2025 Notes)		Capped Call Derivative Assets (2029 Notes)		Embedded Derivative Liability (2025 Notes)		Embedded Derivative Liability (2029 Notes)
September 30, 2025	46	%	39	%	46	%	39	%
December 31, 2024	37	%	35	%	37	%	35	%


	September 30, 2025		December 31, 2024		Maturity	Interest Rate
Term Facilities	$	101,403	$	313,014	July 2027	7.38%
2029 Notes	270,994		258,043		March 2029	2.50%
2025 Notes	56,683		53,887		December 2025	3.00%
Bank of America, U.S.	—		1,500
Other	5,374		519
Total long-term facilities	434,454		626,963
Less: Current portion of long-term debt	85,423		77,339
Total long-term debt obligations	$	349,031	$	549,624


As of December 31, 2024	$	15,843
Payments	(1,951)
Adjustments (1)	4,989
FX and other	895
As of September 30, 2025	19,776
Less: Current portion as of September 30, 2025	16,499
Long-term portion as of September 30, 2025 (2)	$	3,277


	Ordinary Shares	Ordinary Shares - Amount		Additional Paid-In Capital		Treasury Stock		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit		Total Stockholders’ Equity
June 30, 2025	55,499	$	84,521	$	2,234,777	$	(1,161)	$	8,113	$	(1,203,411)	$	1,122,839
Stock-based compensation plans	4	(1)		10,247		(34)		—		—		10,212
Net income	—	—		—		—		—		26,784		26,784
Other comprehensive loss	—	—		—		—		(2,605)		—		(2,605)
September 30, 2025	55,503	$	84,520	$	2,245,024	$	(1,195)	$	5,508	$	(1,176,627)	$	1,157,230

June 30, 2024	54,404	$	83,070	$	2,204,580	$	(195)	$	(52,819)	$	(992,094)	$	1,242,542
Stock-based compensation plans	2	42		8,352		39		—		—		8,433
Net income	—	—		—		—		—		32,953		32,953
Other comprehensive income	—	—		—		—		26,116		—		26,116
September 30, 2024	54,406	$	83,112	$	2,212,932	$	(156)	$	(26,703)	$	(959,141)	$	1,310,044


	Nine Months Ended September 30,
	2025		2024
Operating Activities:
Net (loss) income	$	(273,377)	$	7,343
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation	26,904		26,984
Depreciation	21,008		18,683
Amortization of debt issuance costs	17,259		15,692
Remeasurement of derivative instruments	(16,990)		400
Amortization of intangible assets	13,186		12,960
Amortization of operating lease assets	10,732		6,918
Remeasurement of contingent consideration to fair value	5,464		338
Deferred income tax expense	4,066		9,093
Loss on investment revaluation - Ceribell, Inc.	3,622		—
Loss on debt extinguishment	2,651		25,482
Impairments of investments	1,112		5,768
Other	2,427		1,453
Changes in operating assets and liabilities:
Accounts receivable, net	(5,830)		17,425
Inventories	(8,100)		(13,895)
Other current and non-current assets	50,582		(14,841)
Accounts payable and accrued current and non-current liabilities	(36,051)		(23,383)
Taxes payable	(13,575)		2,628
SNIA environmental liability	363,815		—
Litigation provision liability	3,038		5,283
Net cash provided by operating activities	171,943		104,331
Investing Activities:
Purchases of property, plant, and equipment	(48,817)		(36,701)
Proceeds from investments	6,522		—
Other	(358)		(751)
Net cash used in investing activities	(42,653)		(37,452)
Financing Activities:
Repayment of long-term debt obligations	(216,813)		(243,174)
Shares repurchased from employees for minimum tax withholding	(3,625)		(8,071)
Proceeds from long-term debt obligations	—		335,513
Payment of debt extinguishment costs	—		(38,953)
Purchase of capped calls	—		(31,637)
Proceeds from unwind of capped calls	—		22,523
Payment of contingent consideration	—		(13,750)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Service-based RSUs	$	4,715	$	4,288	$	12,784	$	13,662
Service-based SARs	3,494		3,480		9,628		10,003
Market performance-based RSUs	629		257		1,558		1,303
Operating performance-based RSUs	748		255		2,030		1,119
Employee share purchase plan	361		279		904		897
	$	9,947	$	8,559	$	26,904	$	26,984


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Cardiopulmonary
United States	$	71,946	$	62,504	$	204,023	$	177,954
Europe (1)	50,052		40,894		143,605		120,387
Rest of World (1)	81,220		68,841		231,182		203,503
	203,218		172,239		578,810		501,844
Neuromodulation
United States	118,390		112,906		343,950		330,518
Europe (1)	14,521		11,922		47,445		40,919
Rest of World (1)	16,614		15,033		48,693		45,172
	149,525		139,861		440,088		416,609
Other Revenue (2)	5,010		6,020		8,234		13,154
Totals (3)
United States	190,447		179,828		548,085		519,985
Europe (1)	67,683		52,815		194,160		158,414
Rest of World (1)	99,623		85,477		284,887		253,208
	$	357,753	$	318,120	$	1,027,132	$	931,607


	Foreign Currency Translation Adjustments (1)
December 31, 2024	$	(80,170)
Other comprehensive income before reclassifications, before tax	85,678
Tax expense	—
Other comprehensive income before reclassifications, net of tax	85,678



Net current-period other comprehensive income, net of tax	85,678
September 30, 2025	$	5,508


	Foreign Currency Translation Adjustments (1)
December 31, 2023	$	(27,883)
Other comprehensive income before reclassifications, before tax	1,180
Tax expense	—
Other comprehensive income before reclassifications, net of tax	1,180



Net current-period other comprehensive income, net of tax	1,180
September 30, 2024	$	(26,703)


	Nine Months Ended September 30, 2025
	Shares	Weighted Average Grant Date Fair Value
Service-based SARs	1,038	$	17.87
Service-based RSUs	566	39.98
Market performance-based RSUs	82	41.67
Operating performance-based RSUs	93	39.98


	Cardiopulmonary		Neuromodulation		Total
December 31, 2024	$	351,252	$	398,754	$	750,006

Foreign currency adjustments	41,028		—		41,028
September 30, 2025	$	392,280	$	398,754	$	791,034


	September 30, 2025		December 31, 2024
Raw materials	$	77,895	$	71,949
Work-in-process	17,971		12,322
Finished goods	71,672		63,295
	$	167,538	$	147,566


	September 30, 2025		December 31, 2024
Legal and professional costs	$	18,481	$	17,379
Italian MedTech payback measure	12,255		15,981
Contract liabilities	11,084		10,848
Operating lease liabilities	9,001		9,040
Provisions for agents, returns, and other	4,948		6,744
Royalty accrual	4,660		4,466
Interest payable	3,235		9,479
Current derivative liabilities	1,888		2,915
Research and development costs	1,353		6,167
Restructuring liabilities	—		2,003
Other accrued expenses	25,324		33,463
	$	92,229	$	118,485


	Twelve Months Ended December 31, 2024						Twelve Months Ended December 31, 2023
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	382,564	$	17,389	$	399,953	$	382,295	$	15,430	$	397,725
Gross profit	870,873		(17,389)		853,484		771,250		(15,430)		755,820
Selling, general, and administrative	526,265		(17,389)		508,876		518,129		(15,430)		502,699


	Three Months Ended March 31, 2025						Three Months Ended March 31, 2024
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	96,080	$	4,521	$	100,601	$	87,522	$	4,182	$	91,704
Gross profit	220,775		(4,521)		216,254		207,390		(4,182)		203,208
Selling, general, and administrative	133,667		(4,521)		129,146		129,863		(4,182)		125,681


	Three Months Ended September 30, 2024						Nine Months Ended September 30, 2024
	As Previously Reported		Adjustment		As Revised		As Previously Reported		Adjustment		As Revised
Cost of sales	$	92,856	$	4,235	$	97,091	$	280,088	$	12,404	$	292,492
Gross profit	225,264		(4,235)		221,029		651,519		(12,404)		639,115
Selling, general, and administrative	131,661		(4,235)		127,426		390,642		(12,404)		378,238


	September 30, 2025		December 31, 2024
Available Short-term Liquidity
Cash and cash equivalents	$	646,079	$	428,858
Availability under the 2021 First Lien Credit Agreement	225,000		225,000
	$	871,079	$	653,858
Working Capital
Current assets	$	1,097,149	$	1,127,186
Current liabilities	827,588		392,125
	$	269,561	$	735,061
Debt Obligations
Current portion of long-term debt	$	85,423	$	77,339
Short-term unsecured borrowing arrangements	17		665
Current debt obligations	85,440		78,004
Long-term debt obligations (1)	349,031		549,624
	$	434,471	$	627,628


Exhibit Number						Description
31.1*						Certification of the Chief Executive Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*						Certification of the Chief Financial Officer of LivaNova PLC pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*						Certification of the Chief Executive Officer and Chief Financial Officer of LivaNova PLC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*						Interactive Data Files Pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL: (i) the Condensed Consolidated Statements of Income (Loss) for the three and nine months ended September 30, 2025 and 2024, (ii) the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2025 and 2024, (iii) the Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024, (iv) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024, and (v) the Notes to the Condensed Consolidated Financial Statements
104*						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


	LIVANOVA PLC


Date: November 5, 2025	By:	/s/ VLADIMIR MAKATSARIA
		Vladimir Makatsaria
		Chief Executive Officer
		(Principal Executive Officer)


	LIVANOVA PLC


Date: November 5, 2025	By:	/s/ ALEX SHVARTSBURG
		Alex Shvartsburg
		Chief Financial Officer
		(Principal Accounting and Financial Officer)